NewsBenzingaAscendiant Capital mantiene la recomendación de compra sobre Atossa Therapeutics y eleva el precio objetivo a 25 dólares. Ascendiant Capital mantiene la recomendación de compra sobre Atossa Therapeutics y eleva el precio objetivo a 25 dólares. Benzinga 2026.10.01 09:19 (GMT+0) Open on Benzinga Other news American Battery Technology Stock Surges Thursday: What's Happening? Veritone Commences ~$15M Offering Of 20M Common Shares 'Carlyle Warns Private Credit’s AI Push Raises Concentration Risk' - Bloomberg IBM Stock Rises After Unveiling Self-Hosted Deployment for IBM Bob Northland Capital Markets Initiates Coverage On Civeo with Outperform Rating, Announces Price Target of $42 President Trump Says In Time Magazine Interview That May Increase Iran Strikes After Midterms If There Is No Deal; Oil Movements Through Hormuz 'Set A Record' Last Night; Responds To Question On Whether Americans Should Hold The President Responsible...
Northland Capital Markets Initiates Coverage On Civeo with Outperform Rating, Announces Price Target of $42
President Trump Says In Time Magazine Interview That May Increase Iran Strikes After Midterms If There Is No Deal; Oil Movements Through Hormuz 'Set A Record' Last Night; Responds To Question On Whether Americans Should Hold The President Responsible...
